Multifocal white matter lesions associated with the D313Y mutation of the α-galactosidase A gene

Malte Lenders1, Thomas Duning, Michael Schelleckes

  • 1Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital Muenster, Muenster, Germany.

Plos One
|February 9, 2013
PubMed

Insights

The D313Y mutation in the alpha-galactosidase A (GLA) gene is linked to white matter lesions (WML) in young adults. This finding suggests D313Y may be a cause of hereditary small artery disease, necessitating further evaluation.

Area of Science:

  • Neurology
  • Genetics
  • Biochemistry

Background:

  • White matter lesions (WML) are linked to neurological conditions, but their cause in young adults lacking typical risk factors is often unclear.
  • The D313Y mutation in the alpha-galactosidase A (GLA) gene was previously considered nonpathogenic, despite pathogenic GLA mutations causing Fabry disease.

Purpose of the Study:

  • To investigate the clinical diagnosis and mechanisms behind WML in individuals with the D313Y GLA mutation.
  • To determine if the D313Y mutation contributes to neurological damage and WML.

Main Methods:

  • Clinical, biochemical, and genetic examinations were performed on a family with the D313Y GLA mutation.
  • Advanced magnetic resonance imaging (MRI) was used to analyze white matter lesions.
  • Alpha-galactosidase A (GLA) enzyme activity was measured in leukocytes and plasma.

Main Results:

  • Seven family members with the D313Y mutation exhibited neurological symptoms and WML.
  • Family members without the D313Y mutation showed no WML.
  • The D313Y mutation led to normal GLA enzyme activity in leukocytes but significantly reduced activity in plasma.

Conclusions:

  • The GLA D313Y mutation is associated with neurological damage and WML, particularly in young adults without traditional risk factors.
  • D313Y should be considered in the differential diagnosis of hereditary small artery diseases of the brain.
  • Further evaluation of patients with the D313Y mutation is warranted due to potential therapeutic implications.

Related Concept Videos